Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

It can be taken with or without food. A daily oral dose of 400 mg is recommended. The common side effects associated with ...

Data from the pivotal trial also showed the safety profile of Kisqali at the 400mg dose was well-tolerated with generally low-grade symptomatic adverse events. An updated analysis from the NATALEE ...

Data from the pivotal trial also showed that the safety profile of Kisqali at the 400mg dose was well-tolerated, with generally low-grade symptomatic adverse events. The European Commission (EC ...

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

NICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England and Wales, three months after rejecting it on cost grounds, via the ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Data from the pivotal trial also showed that Kisqali's safety profile at the 400mg dose was well-tolerated, with generally low-grade symptomatic adverse events. Following the CHMP’s positive ...